Abstract
Cot/Tpl-2/MAP3K8 is a serine/threonine protein kinase that is essential for lipopolysaccharide (LPS)-induced activation of the MEK/ERK pathway in macrophages as demonstrated in Cot/Tpl-2-deficient mice. Cot/Tpl-2 kinase activation plays an integral role in the production of pro-inflammatory cytokines such as TNF and IL-1β in this immune cell type. Elevated levels of these cytokines have been clinically implicated as mediators of a number of autoimmune diseases, in particular, the pain and joint destruction of rheumatoid arthritis. By inference, pharmaceutical agents that inhibit Cot/Tpl-2 kinase have the potential to be novel and effective therapies for the treatment of these diseases. This review will describe the physiological regulation and importance of Cot/Tpl-2 in inflammation as well as the landscape of small molecules that have been reported as Cot/Tpl-2 inhibitors.
Keywords: Cot/Tpl-2, serine/threonine kinase, LPS, macrophages, kinase inhibitors
Current Topics in Medicinal Chemistry
Title: Cot/Tpl-2 Protein Kinase as a Target for the Treatment of Inflammatory Disease
Volume: 9 Issue: 7
Author(s): D. George and A. Salmeron
Affiliation:
Keywords: Cot/Tpl-2, serine/threonine kinase, LPS, macrophages, kinase inhibitors
Abstract: Cot/Tpl-2/MAP3K8 is a serine/threonine protein kinase that is essential for lipopolysaccharide (LPS)-induced activation of the MEK/ERK pathway in macrophages as demonstrated in Cot/Tpl-2-deficient mice. Cot/Tpl-2 kinase activation plays an integral role in the production of pro-inflammatory cytokines such as TNF and IL-1β in this immune cell type. Elevated levels of these cytokines have been clinically implicated as mediators of a number of autoimmune diseases, in particular, the pain and joint destruction of rheumatoid arthritis. By inference, pharmaceutical agents that inhibit Cot/Tpl-2 kinase have the potential to be novel and effective therapies for the treatment of these diseases. This review will describe the physiological regulation and importance of Cot/Tpl-2 in inflammation as well as the landscape of small molecules that have been reported as Cot/Tpl-2 inhibitors.
Export Options
About this article
Cite this article as:
George D. and Salmeron A., Cot/Tpl-2 Protein Kinase as a Target for the Treatment of Inflammatory Disease, Current Topics in Medicinal Chemistry 2009; 9 (7) . https://dx.doi.org/10.2174/156802609789007345
DOI https://dx.doi.org/10.2174/156802609789007345 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Failure of Immune Homeostasis - The Consequences of Under and Over Reactivity
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The Surface Plasmon Resonance Imaging Sensor for Papain Based on Immobilized Cystatin
Protein & Peptide Letters Current Problems with Non-Specific COX Inhibitors
Current Pharmaceutical Design The Identification, Characterization and Optimization of Small Molecule Probes of Cysteine Proteases: Experiences of the Penn Center for Molecular Discovery with Cathepsin B and Cathepsin L
Current Topics in Medicinal Chemistry Mast Cells as Critical Effectors of Host Immune Defense against Gram-negative Bacteria
Current Medicinal Chemistry Stem Cell Pharmacogenomics
Current Topics in Medicinal Chemistry Immunosuppressive Properties of Mesenchymal Stem Cells: Advances and Applications
Current Molecular Medicine Protective Potential of Uric Acid, Folic Acid, Glutathione and Ascorbic Acid Against the Formation of Toxic Met-Myoglobin
Protein & Peptide Letters Molecular Phenotype of CXCL12β 3UTR G801A Polymorphism (rs1801157) Associated to HIV-1 Disease Progression
Current HIV Research Phenylpyazoleanilides as Potent Inhibitor of IL-15 Dependent T Cell Proliferation. Part 2: Discovery of a New Drug Candidate, Y-320
Letters in Drug Design & Discovery Cytokines and Growth Factors in the Treatment of Osteoarthritis: What Could be the Best Disease Modifying Drugs
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Human Eosinophils - Potential Pharmacological Model Applied in Human Histamine H<sub>4</sub> Receptor Research
Current Medicinal Chemistry Non Peptidic αvβ3 Antagonists: Recent Developments
Current Medicinal Chemistry Bioremediation of Toxic Heavy Metals: A Patent Review
Recent Patents on Biotechnology Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research
CNS & Neurological Disorders - Drug Targets Anti-inflammatory Action of Green Tea
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Alkaloids Pharmacological Activities - Prospects for the Development of Phytopharmaceuticals for Neurodegenerative Diseases
Current Pharmaceutical Biotechnology Biomarkers of Subclinical Atherosclerosis and Natural Products as Complementary Alternative Medicine
Current Pharmaceutical Design Atom Based 3D-QSAR, Molecular Docking and Density Functional Theory Approaches to Identify Novel JNK-1 Inhibitor
Combinatorial Chemistry & High Throughput Screening ADAMs and Ectododomain Proteolytic Shedding in Leucocyte Migration: Focus on L-Selectin and ADAM17
Current Immunology Reviews (Discontinued)